WNX Shares Wellnex Life Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Consumer health portfolio expansion offers high growth potential from new product commercialization.
Signal breakdown
- ▸Commercialization pipeline, but limited liquidity increases risk.
- ▾Below 50-day MA (-16.03%)
- ▾Near 52-week low (12.1% of range)
Is WNX a buy right now?
Trend: WNX is trading below the 50-day average (-17.50%), RSI 22 — oversold territory, with a 3-month return of +32.00%.
Valuation & quality: Wellnex Life Limited trades on forward P/E 1.3, price-to-book 0.65; fundamentals show net margin -18.3%, return on equity -48.6%, revenue growth 2.2% year on year.
Our screen: WATCH (score 0) — Consumer health portfolio expansion offers high growth potential from new product commercialization.
Computed from end-of-day data; not personal advice.
Our track record with WNX
First flagged in our daily picks as WATCH on 2026-10-23 at $0.07 — +0% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -30.00% | +14.30% | -25.00% | -16.70% | +20.00% | +33.30% | +0.00% | -12.50% |
Fundamentals
Technical signals
About Wellnex Life Limited
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia and New Zealand.
Sector: Consumer Defensive · Industry: Packaged Foods · Australia · Website
Related Consumer Staples picks
Browse: all ASX stocks · Consumer Staples picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.